Page 61 - Read Online

Page 136 Saliba et al. Cancer Drug Resist 2021;4:125-42 I http://dx.doi.org/10.20517/cdr.2020.95

evaluating the causes of loss of response or relapse in clinical samples are needed to elucidate the patterns
and mechanisms of resistance. It also remains crucial to explore modified dosing schedules for HMAs
as a strategy to avoid acquired HMA resistance based on the results of recent studies with single-agent
decitabine and azacitidine.

DECLARATIONS
Authors’ contributions
Conducted literature review and wrote first draft: Saliba AN, John AJ
Edited manuscript: Saliba AN, John AJ, Kaufmann SH

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was in part by a grant from the NIH (R01 CA225996 to S.H.K.) and a fellowship to John AJ from
the Mayo Foundation for Education and Research.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30.
2. Löwenberg B, Ossenkoppele GJ, van Putten W, et al; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON), German
AML Study Group (AMLSG), Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older
patients with acute myeloid leukemia. N Engl J Med 2009;361:1235-48.
3. Prébet T, Boissel N, Reutenauer S, et al; Acute Leukemia French Association, Groupe Ouest-Est des leucémies et autres maladies du sang
(GOELAMS), Core Binding Factor Acute Myeloid Leukemia (CBF AML) intergroup. Acute myeloid leukemia with translocation (8;21)
or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J
Clin Oncol 2009;27:4747-53.
4. Wahlin A, Markevärn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid
leukaemia. Br J Haematol 2001;115:25-33.
5. Farag SS, Archer KJ, Mrózek K, et al; Cancer and Leukemia Group B 8461. Pretreatment cytogenetics add to other prognostic factors
predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from
Cancer and Leukemia Group B 8461. Blood 2006;108:63-73.
6. Grimwade D, Walker H, Harrison G, et al; Medical Research Council Adult Leukemia Working Party. The predictive value of hierarchical
cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom
Medical Research Council AML11 trial. Blood 2001;98:1312-20.
7. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007;25:1908-15.
8. Krug U, Büchner T, Berdel WE, Müller-Tidow C. The treatment of elderly patients with acute myeloid leukemia. Dtsch Arztebl Int
2011;108:863-70.
9. Othus M, Appelbaum FR, Petersdorf SH, et al. Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction
therapy. Biol Blood Marrow Transplant 2015;21:559-64.
10. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy
in younger patients with acute myeloid leukemia. Blood 2013;121:4854-60.